An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire

Neville, Catriona; Venables, Vanessa; Aslet, Margaret; Nduka, Charles; Kannan, Ruben Y.

doi:10.1016/j.bjps.2017.05.048

Cited by 20 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os autores relatam que as doses são específicas para cada paciente, já que dependem de sexo, tempo em que a pessoa já se encontra com paralisia, etiologia, idade e resposta do organismo. Neville et al (2017) trouxeram que os sintomas relatados pelos pacientes é outro dado que deve ser observado antes de se concluir o plano de tratamento. Portanto, o protocolo deve ser individualizado e definido após examinar cada paciente.…”

Section: Discussionunclassified

A utilização da toxina botulínica no tratamento da paralisia facial periférica

Andalécio

Andrade

Lima

et al. 2021

RSD

View full text Add to dashboard Cite

A Paralisia Facial Periférica (PFP) é um estado de paralisação ou enfraquecimento dos músculos da face que causam limitações motoras e estéticas ao paciente com esta condição. Um meio de tratamento para a PFP que vem ganhando destaque é a utilização de toxina botulínica no lado contralateral ao acometido pela condição. Esta toxina é coletada através dos esporos da bactéria Clostridium botulinum, e atua inibindo a liberação de acetilcolina na junção neuromuscular, diminuindo hiperfunção muscular e devolvendo simetria a face do paciente. Portanto, este estudo tem como objetivo alcançar o conhecimento do melhor protocolo de aplicação da toxina na paralisia, além de qual sorotipo usar e a capacidade de melhoria na qualidade de vida do paciente. O estudo consta com uma revisão integrativa de caráter básico, qualitativa, descritiva-explicativa com base nas principais plataformas de pesquisa buscando os termos paralisia facial e toxina botulínica. Foram incluídos artigos no intervalo de tempo de 2011 a 2021 na língua inglesa e a busca resultou em 17 artigos. Em todos os artigos revisados o sorotipo A da toxina botulínica foi o único utilizado para o tratamento, a quantidade de unidades biológicas (UI) e o protocolo foi individualizado para cada paciente isentando de um padrão. A qualidade de vida dos pacientes foi devolvida após se obter melhora na simetria facial e com isso aumento na autoestima além de principalmente, devolver a capacidade de realizar ações musculares coordenadas. Portanto, pode-se concluir que o tratamento da PFP com toxina botulínica é altamente benéfico aos pacientes.

show abstract

Section: Discussionunclassified

A utilização da toxina botulínica no tratamento da paralisia facial periférica

Andalécio

Andrade

Lima

et al. 2021

RSD

View full text Add to dashboard Cite

show abstract

“…The weakness of the study is that the BDS and Jankovic score are not transferrable to AFR and HFS as methods of monitoring disease response; the synkinesis assessment questionnaire being a better tool to use 27 . Despite both BDS and Jankovic being designed for blepharospasm, providing a disability profile both before and after treatment is still a useful measure, such as effect on driving.…”

Section: Discussionmentioning

confidence: 99%

Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia

Bladen

Favor

Litwin

et al. 2020

Clinical Exper Ophthalmology

View full text Add to dashboard Cite

Importance When making a cost‐saving it is important to ensure there is no loss of efficacy. Background Clinical effectiveness and efficiency of incobotulinumtoxinA compared to onabotulinumtoxinA in facial dystonia is unclear. Our aim is to evaluate switching from onabotulinumtoxinA to incobotulinumtoxinA in the treatment of essential blepharospasm (EB), hemifacial spasm (HFS) and aberrant facial nerve regeneration (AFR). Design A retrospective study of a prospective, single‐masked switchover audit from onabotulinumtoxinA to incobotulinumtoxinA. Participants Twenty essential EB, 12 HFS and six AFR patients. Methods A switchover from stable onabotulinumtoxinA to incobotulinumtoxinA using a 1:1 unit ratio and contemporaneous efficacy measures. Two nurse injectors performed the injections over a period of 6 years. Each masked patient received three onabotulinumtoxinA and three incobotulinumtoxinA over a minimum of 2 years. Main Outcome methods At each visit, a blepharospasm disability score (BDS), Jankovic score (JS), subjective improvement (SI), duration of maximum effect (DME) and complications were recorded. A cost comparison per unit dose was made. Results Twenty EB, 12 HFS and six AFR received 114 onabotulinumtoxinA and 114 incobotulinumtoxinA treatments. Both brands had similar efficacy, but SI (P < .01) and DME (P < .05) were higher in the HFS group with incobotulinumtoxinA. Complications included bruising (two onabotulinumtoxinA, one incobotulinumtoxinA) and ptosis (three onabotulinumtoxinA, zero incobotulinumtoxinA). OnabotulinumtoxinA was 33% pricier. Conclusion and Relevance Switching from onabotulinumtoxinA to incobotulinumtoxinA did not result in an inferior outcome for the treatment of facial dystonia and led to a cost‐saving for the department.

show abstract

“…Seven prospective and two retrospective observational cohort studies comparing outcome measures before and after treatment and one randomized controlled clinical trial. 2,4,5,7,8,10,[12][13][14][15] Details of these studies are summarized in Table 2. The number of patients included in these studies ranged from 23 to 99 patients, with a total of 430 patients.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…2 In the other two remaining studies, the muscles in which BTX-A was administered were not specified. 13,14 In five studies, it is explicitly or implicitly described that BTX-A infiltration was performed on both sides of the face. 2,8,10,13,15 The mean total dose ranged from 15.7 to 54 U per session (reported in four studies) 2,7,8,12 and two studies reported a median total dose of 17.7 and 20.0 U per session.…”

Section: Patterns Of Btx-a Treatmentmentioning

confidence: 99%

“…In all studies, an assessment was carried out before and after every injection, based on the SFGS in six studies, 2,4,5,7,8,10 the SAQ in six studies, 4,8,[12][13][14][15] a facial assessment software, 7 a dynamic facial asymmetry ratio (facial photographs), 10 and patient's subjective assessment (complaints, personal appearance, quality of life, social interaction, food intake) in two studies. 5,10 Most patients were reassessed 2-4 wks after BTX-A injection.…”

Section: Functional Outcomes and Self-perceived Improvement With Btx-...mentioning

confidence: 99%

See 1 more Smart Citation

Botulinum Toxin Type A Injection in the Treatment of Postparetic Facial Synkinesis

Tavares¹,

Oliveira²,

Costa³

et al. 2022

Am J Phys Med Rehabil

View full text Add to dashboard Cite

This study aimed to review the recent literature about botulinum toxin type A treatment patterns, including muscle targets, doses, duration of effect, adverse effects, and clinical outcomes in patients with postparetic synkinesis. A bibliographic research of studies published in the last 10 yrs was carried out on PubMed database, using the medical subject heading terms: botulinum toxin and synkinesis. English-language cohort studies or randomized controlled trials about botulinum toxin type A treatment on patients with postparetic synkinesis were eligible for inclusion. Ten studies met the inclusion criteria, seven prospective studies, two retrospective studies, and one randomized controlled trial, involving 23-99 patients. The target facial muscles included frontalis, corrugator supercilli, orbicularis oculi, levator labii superioris, zygomaticus major, orbicularis oris, risorius, buccinator, depressor anguli oris, depressor labii inferioris, mentalis, and platysma. The dose of onabotulinumtoxinA administered per injection site ranged between 0.5 and 10 U. Adverse effects were rare and temporary. The mean duration of onabotulinumtoxinA effect ranges from 66 days to 4 mos. There was a statistically significant improvement in posttreatment evaluation, both in objective and subjective assessments. There is scientific evidence of the benefit of botulinum toxin type A treatment for postparetic synkinesis, but there is lack of standardized treatment protocols.

show abstract

An objective assessment of botulinum toxin type A injection in the treatment of post-facial palsy synkinesis and hyperkinesis using the synkinesis assessment questionnaire

Cited by 20 publications

References 16 publications

A utilização da toxina botulínica no tratamento da paralisia facial periférica

A utilização da toxina botulínica no tratamento da paralisia facial periférica

Switchover study of onabotulinumtoxinA to incobotulinumtoxinA for facial dystonia

Botulinum Toxin Type A Injection in the Treatment of Postparetic Facial Synkinesis

Contact Info

Product

Resources

About